DGAP-Adhoc: Merck KGaA: Merck and GSK agree on Collaboration in Immuno-Oncology
| DGAP-Ad-hoc: Merck KGaA / Key word(s): Alliance
Merck KGaA: Merck and GSK agree on Collaboration in Immuno-Oncology
05-Feb-2019 / 12:53 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Merck KGaA and GlaxoSmithKline plc (GSK) will collaborate closely in the field of immuno-oncology. The cooperation relates to M7824, a bifunctional fusion protein developed by Merck. This is currently in clinical development and targets various forms of cancer that are difficult to treat.
Merck will receive an upfront payment of EUR300 million and is eligible for potential development milestone payments of up to EUR500 million. Merck will also be eligible for further payments upon successfully achieving future approval and commercial milestones of up to EUR2.9 billion. The total potential deal value is up to EUR3.7 billion.
The two companies will jointly develop and commercialize M7824. All profits and costs from the collaboration will be shared equally on a global basis.
In total, eight high priority clinical development studies for M7824 are ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers.
Contact: Friederike Segeberg, Head of Media Relations
05-Feb-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
|
| Language: | English | | Company: | Merck KGaA | | Frankfurter Str. 250 | | 64293 Darmstadt | | Germany | | Phone: | +49 (0)6151 72 - 6328 | | Fax: | +49 (0)6151 72 - 3183 | | E-mail: | [email protected] | | Internet: | www.merck.de | | ISIN: | DE0006599905 | | WKN: | 659990 | | Indices: | DAX | | Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX |
| | | End of Announcement | DGAP News Service |
772413 05-Feb-2019 CET/CEST 
|
Die wichtigsten Finanzdaten auf einen Blick
|
| |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
| Umsatzerlöse1 |
15.327,00 |
14.836,00 |
16.152,00 |
17.534,00 |
19.687,00 |
22.232,00 |
20.993,00 |
| EBITDA1,2 |
4.282,00 |
3.528,00 |
4.066,00 |
4.923,00 |
5.946,00 |
6.504,00 |
5.489,00 |
| EBITDA-Marge3 |
27,94 |
23,78 |
25,17 |
28,08 |
30,20 |
29,26 |
|
| EBIT1,4 |
2.525,00 |
1.727,00 |
2.120,00 |
2.985,00 |
4.179,00 |
4.474,00 |
3.609,00 |
| EBIT-Marge5 |
16,47 |
11,64 |
13,13 |
17,02 |
21,23 |
20,12 |
17,19 |
| Jahresüberschuss1 |
2.610,00 |
3.396,00 |
1.324,00 |
1.994,00 |
3.065,00 |
3.339,00 |
2.834,00 |
| Netto-Marge6 |
17,03 |
22,89 |
8,20 |
11,37 |
15,57 |
15,02 |
13,50 |
| Cashflow1,7 |
2.696,00 |
2.219,00 |
2.856,00 |
3.477,00 |
4.616,00 |
4.259,00 |
3.784,00 |
| Ergebnis je Aktie8 |
5,99 |
7,76 |
3,04 |
4,57 |
7,03 |
7,65 |
6,49 |
| Dividende8 |
1,25 |
1,25 |
1,30 |
1,40 |
1,85 |
2,20 |
1,20 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen. 
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Deloitte
|
| INVESTOR-INFORMATIONEN |
| ©boersengefluester.de |
| Merck |
| WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
| 659990 |
139,700 |
Halten |
60.738,47 |
| KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
| 18,14 |
24,94 |
0,73 |
25,06 |
| KBV |
KCV |
KUV |
EV/EBITDA |
| 2,30 |
16,05 |
2,89 |
12,93 |
| Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23
in % |
Hauptversammlung |
| 2,20 |
2,20 |
1,57 |
25.04.2025 |
| Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
| 15.05.2024 |
01.08.2024 |
14.11.2024 |
06.03.2025 |
| Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
| -12,14% |
-12,32% |
-3,05% |
-13,26% |
|
|
Merck KGaA DE0006599905